Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company regarding its clinical studies [1][2]. Group 1: Class Action Details - Investors who purchased Mereo ADSs between June 5, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has been consistently ranked among the top firms in this area since 2013 [4]. Group 3: Case Background - The lawsuit alleges that Mereo BioPharma provided investors with misleading information regarding the expected results of its Phase 3 clinical studies for setrusumab, which did not meet their primary endpoints [5][6]. - The misleading statements led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in financial damages when the true information was revealed [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Klarna Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to Klarna's September 2025 IPO [1]. Group 1: Class Action Details - Investors who purchased Klarna securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by February 20, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit claims that the Registration Statement issued during Klarna's IPO contained false or misleading statements, particularly regarding the risk of increased loss reserves shortly after the IPO [5]. - It is alleged that the defendants either knew or should have known about the risks associated with Klarna's buy now, pay later loans, leading to materially false public statements [5].

Rosen Law Firm Encourages Franklin BSP Realty Trust, Inc. Investors to Inquire About Securities Class Action Investigation - FBRT [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Franklin BSP Realty Trust, Inc. (NYSE: FBRT) resulting from allegations that Franklin BSP Realty Trust, Inc. may have issued materially misleading business inf ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bath & Body Works, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on March 16, 2026 [1]. Group 1: Class Action Details - Investors who bought Bath & Body Works securities between June 4, 2024, and November 19, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6]. - The lawsuit alleges that Bath & Body Works made materially false and misleading statements regarding its business strategy and financial performance, which led to investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of its Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increased bone density, it did not correlate with a decrease in annualized fracture rates, contrary to the positive statements made by the defendants [6].

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Paysafe Limited (NYSE: PSFE) between March 4, 2025 and November 12, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. SO WHAT: If you purchased Paysafe securities during the Class Period you may be entitled to ...

Core Viewpoint - Rosen Law Firm is reminding sellers of Masonite International Corporation common stock about a class action lawsuit related to material omissions and misrepresentations during the Class Period from June 5, 2023, to February 8, 2024, with a lead plaintiff deadline of April 7, 2026 [1][4]. Group 1: Class Action Details - Investors who sold Masonite common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. - The lawsuit alleges that Masonite made significant omissions regarding Owens Corning's offers to purchase its stock at premiums, which misled investors about the true value of Masonite's shares [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured substantial settlements for investors, including over $438 million in 2019, and has been recognized as a leader in securities class action settlements [3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities during the specified Class Period, highlighting potential investor compensation opportunities [1][2]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, with a lead plaintiff deadline set for April 7, 2026 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, noting that many firms may lack the necessary experience [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Specifics - Inovio Pharmaceuticals is described as a biotechnology company focused on DNA medicines for diseases like HPV [5]. - The lawsuit alleges that Inovio made false or misleading statements regarding the manufacturing of its CELLECTRA device and the prospects of its INO-3107 Biologics License Application, which were overstated [5].

Core Viewpoint - Rosen Law Firm is reminding sellers of Endeavor Group Holdings, Inc. Class A common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to alleged misleading statements and omissions during a specified class period [1][5]. Group 1: Class Action Details - The class action lawsuit seeks to recover damages for investors who sold Endeavor Class A common stock between January 15, 2025, and March 24, 2025, due to allegedly false and misleading statements in the Information Statement filed with the SEC [5]. - Investors who sold shares during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by March 18, 2026, to represent other class members in directing the litigation [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in securities class action services [4]. Group 3: Allegations Against Endeavor - The lawsuit alleges that Endeavor's Information Statement misled investors regarding the true value of its shares and failed to adequately disclose executive earnings and conflicts of interest related to the merger [5].

Core Viewpoint - A class action lawsuit has been initiated against REGENXBIO, Inc. for alleged securities fraud during the period from February 9, 2022, to January 27, 2026, with investors potentially entitled to compensation without upfront costs [1] Group 1: Lawsuit Details - The lawsuit claims that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I, also known as Hurler syndrome [1] - Defendants allegedly made positive assertions about RGX-111's trial success based on favorable biomarker and safety data while concealing adverse facts about the trial's efficacy and safety [1] - Investors reportedly suffered damages when the true details about the trial were revealed [1] Group 2: Legal Representation - Investors wishing to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [1] - The Rosen Law Firm, known for its success in securities class actions, encourages investors to select qualified counsel with a proven track record [1] - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 [1]